Latest News and Press Releases

Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform Expansion of senior team to focus on drug discovery and developmentPlatform combines glycobiology...

Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH Berlin, Germany, February 1, 2022 - Glycotope GmbH, a biotechnology company developing antibodies against proteins...

Glycotope Presents New Data on Carbohydrate-Dependent Antibodies and Fusion-Proteins at the 2021 Society for Immunotherapy of Cancer (SITC) Meeting Glycotope Poster Presentation at the 2021 Society...

NEWS RELEASE Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets Nijmegen, the Netherlands, Berlin, Germany – 27 July 2021 –...

Glycotope Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting Berlin, Germany, June 4, 2021 - Glycotope GmbH, a biotechnology company developing...

Glycotope Announces Poster Presentations at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting Berlin, Germany, April 30, 2021 - Glycotope GmbH, a biotechnology company...

Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1 GlycoBody to be integrated into ONK pre-clinical program ONKT103, for solid tumors. Berlin,...

DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms  Leiden, The Netherlands, and Berlin, Germany, September 21, 2020 -...

Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate Tokyo, Berlin, Basking Ridge, NJ – (July 30, 2018) – Daiichi Sankyo Company, Limited...

Glycotope Initiates Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies ·         GATTO Study to Evaluate Gatipotuzumab and Tomuzotuximab in Advanced and/or Metastatic Solid...